{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:39:37Z","timestamp":1790401177263,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-Alzheimer\u2019s dementias, including vascular dementia (VaD), frontotemporal dementia (FTD), Lewy body dementia (LBD), and Parkinson\u2019s disease dementia (PDD), possess unique characteristics and prognostic factors that remain poorly understood. This study aims to investigate the temporal course of these subtypes and identify the impact of functional, neuropsychiatric, and comorbid medical conditions on prognosis. Additionally, the relationship between hippocampal atrophy, white matter intensities, and disease progression will be examined, along with the identification of key covariates influencing slow or fast progression in non-Alzheimer\u2019s dementias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 196 patients with non-Alzheimer\u2019s dementias who underwent at least three comprehensive evaluations were included, with proportions of VaD, FTD, LBD, and PDD being 50, 19.39, 19.90, and 10.71%, respectively. Patient demographics, comorbidities, neuropsychiatric and neuroimaging parameters, and global evaluation were analyzed using appropriate statistical methods. The study followed patients for a mean duration of 62.57\u2009\u00b1\u200933.45\u2009months (ranging from 11 to 198\u2009months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results from three different visits for each non-AD dementia case demonstrated significant differences in various measures across visits, including functional capacity (BDLAS), cognition (MMSE), and other neuropsychological tests. Notably, certain genotypes and hippocampal atrophy grades were more prevalent in specific subtypes. The results indicate that Fazekas grading and hippocampal atrophy were significant predictors of disease progression, while epilepsy, extrapyramidal symptoms, thyroid dysfunction, coronary artery disease, diabetes mellitus, hypertension, stroke, hyperlipidemia, sleep disorders, smoking, and family history of dementia were not significant predictors. BDLAS and EDLAS scores at the first and second visits showed significant associations with disease progression, while scores at the third visit did not. Group-based trajectory analysis revealed that non-AD cases separated into two reliable subgroups with slow\/fast prognosis, showing high reliability (Entropy\u2009=\u20090.790, 51.8 vs. 48.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides valuable insights into the temporal course and prognostic factors of non-Alzheimer\u2019s dementias. The findings underscore the importance of considering functional, neuropsychological, and comorbid medical conditions in understanding disease progression. The significant associations between hippocampal atrophy, white matter intensities, and prognosis highlight potential avenues for further research and therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2023.1240093","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:29:23Z","timestamp":1697606963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors affecting progression of non-Alzheimer dementia: a retrospective analysis with long-term follow-up"],"prefix":"10.3389","volume":"14","author":[{"given":"Reza","family":"Ghouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevra","family":"\u00d6ks\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Ta\u015fdelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur","family":"\u00d6zge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"104946","DOI":"10.1016\/j.nbd.2020.104946","article-title":"Genetic architecture of common non-Alzheimer\u2019s disease dementias","volume":"142","author":"Guerreiro","year":"2020","journal-title":"Neurobiol Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.dadm.2019.01.002","article-title":"Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegeneration","volume":"11","author":"Smith","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00702-014-1304-1","article-title":"Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium","volume":"122","author":"Alafuzoff","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ene.13467","article-title":"An assessment of Movement Disorder Society task force diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease","volume":"25","author":"Uysal-Cant\u00fcrk","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/ATVBAHA.119.311908","article-title":"Epidemiology of vascular dementia","volume":"39","author":"Wolters","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1212\/CON.0000000000001124","article-title":"Vascular cognitive impairment and dementia","volume":"28","author":"Chang Wong","year":"2022","journal-title":"Continuum"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1239995","DOI":"10.3389\/fneur.2023.1239995","volume":"14","author":"\u00d6zge","year":"2023","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/brain\/awp280","article-title":"Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study","volume":"133","author":"Molano","year":"2010","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","article-title":"A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia","volume":"66","author":"Huey","year":"2006","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O\u2019Brien","year":"2015","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.00000000000049","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"90","author":"McKeith","year":"2018","journal-title":"Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","article-title":"Age, neuropathology, and dementia","volume":"360","author":"Savva","year":"2009","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","article-title":"Age, APOE and sex: triad of risk of Alzheimer\u2019s disease","volume":"160","author":"Riedel","year":"2016","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/HYP.0000000000000053","article-title":"Impact of hypertension on cognitive function: a scientific statement from the American Heart Association","volume":"68","author":"Iadecola","year":"2016","journal-title":"Hypertension"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jns.2019.01.026","article-title":"Association between hypertension and dementia: a systematic review and meta-analysis","volume":"398","author":"Iadecola","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.379","article-title":"A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia","volume":"16","author":"Aarsland","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JAD-2010-1355","article-title":"Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer\u2019s disease: the role of depression and apathy","volume":"20","author":"Palmer","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/s0025-7125(02)00008-1","article-title":"Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention","volume":"86","author":"Rom\u00e1n","year":"2002","journal-title":"Med Clin North Am."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40263-015-0281-8","article-title":"Pharmacological treatment of vascular dementia: a network meta-analysis of randomized controlled trials","volume":"29","author":"Wang","year":"2015","journal-title":"CNS Drugs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1474-4422(03)00305-3","article-title":"Vascular cognitive impairment","volume":"2","author":"O\u2019Brien","year":"2003","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000091047","article-title":"Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney stroke study","volume":"21","author":"Sachdev","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","article-title":"Alzheimer\u2019s disease neuroimaging initiative. Using the Alzheimer\u2019s disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer\u2019s disease","volume":"18","author":"Veitch","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/arclin\/acx112","article-title":"Cognitive and neuropsychiatric correlates of functional impairment across the continuum of no cognitive impairment to dementia","volume":"33","author":"Burton","year":"2018","journal-title":"Arch Clin Neuropsychol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ageing\/afn095","article-title":"Alcohol, dementia and cognitive decline in the elderly: a systematic review","volume":"37","author":"Peters","year":"2008","journal-title":"Age Ageing"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1240093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:29:25Z","timestamp":1697606965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1240093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":28,"alternative-id":["10.3389\/fneur.2023.1240093"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1240093","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"article-number":"1240093"}}